Passage Bio, Inc. PASG
3.98 USD +0.52 (+14.88%)
At closeNov 6, 2026, 4:00 PM EST
3.97 0.00 -0.13%
After hours · Nov 6, 4:00 PM ET
3.39 Day range 4.00
3.32 52-week range 19.85
- YTD
- -66.31%
- 1 year
- -38.94%
News
benzinga.com Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47) by 29.68 percent. This is a 17.57 percent increase over losses of $(2.96)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…- benzinga.com 9 Health Care Stocks Moving In Wednesday's After-Market Session Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
benzinga.com Passage Bio, Remix Therapeutics Sign All-Stock Business Combination Agreement; Combined Entity To Operate Under Remix Therapeutics, RMTX Ticker On Nasdaq Passage Bio, Inc. (Nasdaq: PASG) ("Passage Bio") and Remix Therapeutics, Inc. ("Remix"), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and…
benzinga.com Chardan Capital Downgrades Passage Bio to Neutral, Lowers Price Target to $7 Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $21 to $7.
benzinga.com This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday Wall Street analysts changed outlook for top names, including downgrading Mohawk Industries and Passage Bio. See analyst ratings for these stocks.- benzinga.com Oppenheimer Maintains Outperform on Passage Bio, Lowers Price Target to $15 Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers the price target from $30 to $15.
benzinga.com Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8 Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and lowers the price target from $32 to $8.
benzinga.com Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary down 1.2%. Investar beats earnings.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.
benzinga.com Reported Earlier: Passage Bio Receives FDA Guidance Requiring Randomized Registrational Trial For PBFT02 in FTD-GRN, Evaluates Next Steps In Clinical Development Regulatory & Program UpdateThe Company has completed a Type C meeting with the FDA to seek guidance on key elements of a future registrational trial of PBFT02 for FTD-GRN patients. Based on the…
benzinga.com Reported Earlier: Passage Bio Initiates Strategic Review, Exploring Mergers, Acquisitions, Partnerships, And Other Options To Maximize Shareholder Value Corporate UpdateThe Company has initiated a review of strategic alternatives to maximize shareholder value. These strategic alternatives may include merger or acquisition transactions, a reverse…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Passage Bio Reports Updated Data From Ongoing Phase 1/2 upliFT-D Clinical Trial Evaluating PBFT02 For Treatment Of Frontotemporal Dementia With Granulin Mutations PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30 Oppenheimer analyst Jay Olson initiates coverage on Passage Bio (NASDAQ:PASG) with a Outperform rating and announces Price Target of $30.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $23 Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $67 to $23.
- benzinga.com Passage Bio Q4 EPS $(4.09) Misses $(2.68) Estimate Passage Bio (NASDAQ:PASG) reported quarterly losses of $(4.09) per share which missed the analyst consensus estimate of $(2.68) by 52.5 percent. This is a 2.25 percent decrease over losses of $(4.00)…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $21 Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and raises the price target from $6 to $21.
benzinga.com Passage Bio Q3 EPS $(2.44) Beats $(2.80) Estimate Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.80) by 12.86 percent. This is a 60.33 percent increase over losses of $(6.15)…- benzinga.com Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $67 Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $260 to $67.
- benzinga.com Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $10 Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $40 to $10.
benzinga.com Wedbush Maintains Outperform on Passage Bio, Raises Price Target to $40 Wedbush analyst Yun Zhong maintains Passage Bio (NASDAQ:PASG) with a Outperform and raises the price target from $3 to $40.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst consensus estimate of $(0.21) by 1309.52 percent. This is a 41.85 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Chardan Capital Maintains Buy on Passage Bio, Maintains $6 Price Target Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and maintains $6 price target.
- benzinga.com Passage Bio Reports Interim Data From upliFT-D Showing Durable CSF PGRN Elevation And Reduced Plasma NfL Versus Natural History In FTD-GRN PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural historyDose 2, 50% lower than Dose 1,…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $6 Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $7 to $6.
- benzinga.com Passage Bio Reported Updated Data From The Ongoing Phase 1/2 upliFT-D Trial Of PBFT02 For Frontotemporal Dementia With Granulin Mutations Updated interim data from FTD-GRN patients treated with Dose 1 PBFT02:BiomarkersDose 1 of PBFT02 treatment resulted in a robust and durable increase in PGRN expression.PBFT02 consistently increased…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Wedbush Assumes Passage Bio at Outperform, Announces Price Target of $4 Wedbush analyst Yun Zhong assumes Passage Bio (NASDAQ:PASG) with a Outperform rating and announces Price Target of $4.
- benzinga.com Chardan Capital Maintains Buy on Passage Bio, Maintains $7 Price Target Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and maintains $7 price target.
- benzinga.com Canaccord Genuity Maintains Buy on Passage Bio, Maintains $13 Price Target Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and maintains $13 price target.
- benzinga.com Passage Bio Q3 2024 GAAP EPS $(0.31) Misses $(0.28) Estimate, Cash, Cash Equivalents And Marketable Securities Were $84.8M Expected To Provide Cash Runway To The End Of Q2 2026 Passage Bio (NASDAQ:PASG) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 36.73 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session